Drug-induced adverse events, particularly organ toxicities, account for most drug recalls and delays experienced in gaining regulatory approvals. So what are pre-clinical safety groups doing to better detect and predict cardiotoxicity, hepatotoxicity, immunogenicity, genotoxicity and other types of toxicities early in drug development? Cambridge Healthtech Institute’s seventh annual conference on Functional Screening for Drug Safety Testing focuses on the most innovative tools, assays, models and biomarkers, that are being used for detecting and predicting idiosyncratic and drug-induced toxicities. This conference will bring together leading experts in drug safety, from industry, academia and government/regulatory agencies, to discuss the appropriate use of in silico, in vitro and in vivo tools, leading to informed decision-making.
Who should attend: This conference is largely designed around topics that are relevant to pharmacologists, toxicologists, and scientists in early development who are involved in safety/toxicology testing, drug metabolism studies, compound screening, and biomarker discovery. However, scientists and clinicians from both industry and academia who are involved in translational research will likely benefit from learning about the new tools and methodologies that are being developed to test drug safety in the early stages of the drug pipeline. Technology and service providers and CROs offering tools for drug safety screening will enjoy the active networking and collaboration opportunities.
Topics will include, but are not limited to:
- New Adaptive in vitro Assays: Use of Stem Cells, 3D Cell Cultures, Label-Free Assays, High-Throughput Assays
- Challenges with In vitro to in vivo Translation
- In Vivo Models: Primates, Rodents and Alternative Species
- Criteria for Dose and Species Selection
- Validation and Use of Novel Translational Safety Biomarkers
- Use of Novel Technologies: Microfluidics-based Platforms, Imaging Tools
- Comparing Safety Tests for Small Molecules Versus Biologics
- Safety Concerns Around Epigenetic Targets and Drugs
- Collaborative Initiatives for Safety Assessments
- Outsourcing Safety Testing: What and When to Outsource
Tentative Topics for Conference Short Courses include:
• Addressing Safety Concerns for Biologic Entities: Monoclonals, ADCs, Bispecifics
• Drug Metabolism and Its Role in Toxicity
• Mechanistic Insights into Toxicity: Role of Innate Immunity, Mitochondrial Dysfunction, Drug Transporters
• Use of Stem Cells for Drug Safety Screening
Scientists who wish to present their knowledge and expertise to their colleagues as a podium or poster presentation are asked to submit an abstract.
Click here to submit a speaking proposal. Remember to specify the conference that you are interested in and please provide your full contact information.
Visit www.worldpharmacongress.com to register for a very special early-bird discounted rate.
The deadline for submission is November 1, 2013.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the conference, contact:
Tanuja Koppal, Ph.D.
Cambridge Healthtech Institute
Phone: (+1) 973-525-4667
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431